SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Radiation Oncology Consultation — Nelson Mandela — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Nelson Mandela |
|---|
| Date of birth | 1918-07-18 |
|---|
| Identifiers | MRN HR-ML021-SYN-TD; SSN (made up) 000-21-6718 |
|---|
| Document date | 2001-04-14 |
|---|
| Author | Pieter van Zyl, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Man of 82 with newly diagnosed prostate adenocarcinoma, Grade Group 3, PSA 6.4 ng/mL, cT1c, NCCN unfavorable intermediate risk, found after a rising PSA on monitoring. Please advise on curative treatment, including radiotherapy with short-term androgen deprivation, and whether observation is reasonable at his age. [S]
Urgency: Routine, within four to six weeks. [S]
Questions for the consultant:
- Do you agree with the risk group, and is staging complete with the PSMA PET/CT?
- What are his curative options at 82, and is observation a reasonable choice?
- If radiotherapy is chosen, should androgen deprivation be added, for how long, and how should it start?
- Does his earlier prostate operation change the choice of technique or his risk of urinary side effects?
- What monitoring is needed during and after treatment, including PSA follow-up, and which parts should primary care manage?
History of Present Illness
Mr. Mandela is seen at the request of Dr. Mokoena for newly diagnosed prostate cancer. A rise in PSA on routine monitoring led to an MRI and a targeted biopsy, which showed Grade Group 3 adenocarcinoma in 3 of 14 cores. He has mild urinary frequency, with an IPSS of 7, and no bone pain, weight loss, or blood in the urine. Decades ago part of his prostate was removed for benign enlargement. He had tuberculosis in the past, treated, with no symptoms since. He is independent, walks every morning, and keeps a full schedule of work and travel. He wants to understand all the options before deciding. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Nelson Rolihlahla Mandela was born in Mvezo, in the Eastern Cape, on 18 July 1918. [D]
- Mandela was convicted with seven co-accused in the Rivonia Trial on 11 June 1964 and sentenced to life imprisonment the next day. He was held on Robben Island, moved to Pollsmoor Prison on 31 March 1982 and to Victor Verster Prison near Paarl on 7 December 1988, and was released from Victor Verster on 11 February 1990. [D]
- In 1985 Mandela had prostate surgery while imprisoned. His urologist said in July 2001 that the gland had been enlarged and was causing a urinary blockage, and that part of it was removed. [D]
- Mandela was taken to hospital on 12 August 1988 and diagnosed with tuberculosis; public reports describe it as early tuberculosis, treated at the Constantiaberg Medi-clinic, after which he was moved to Victor Verster Prison. [D]
- His doctors said publicly in 2001 that he had been monitored regularly with the prostate-specific antigen (PSA) test, that a slight rise in the PSA led to a biopsy of the prostate, and that the biopsy confirmed microscopic cancer within the gland. News reports said the raised blood level was first found in November 2000. [D]
- Mandela was inaugurated as South Africa's first democratically elected president on 10 May 1994 and stepped down in 1999 after one term. [D]
4 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolide | One tablet once daily for four weeks | Oral route | 2001-04-14 to 2001-05-12 | completed | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2001-04-14 | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate cancer | active | confirmed |
C61 | S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D). |
| Hormone-sensitive prostate cancer | active | confirmed |
Z19.1 | S — Synthetic status in the modern episode. |
| Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognition | active | confirmed |
Z79.899 | S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| History of pulmonary tuberculosis, treated, with no symptoms since | resolved | confirmed |
Z86.11 | S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic. |
Physical Exam
Vital signs recorded on 2001-04-14; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Well |
| Abdomen | Soft; bladder not palpable |
| Musculoskeletal | No spinal tenderness |
| Lymph nodes | No inguinal or supraclavicular nodes |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2001-04-14 | DXA Femur [T-score] Bone density | -1.4 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 2001-04-14 | DXA Lumbar spine [T-score] Bone density | -0.6 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Normal | S |
| 2001-04-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | | | S |
Assessment
- Prostate adenocarcinoma, cT1c N0 M0, Grade Group 3, PSA 6.4 ng/mL, NCCN unfavorable intermediate risk (C61). I agree with the risk group: Grade Group 3 alone places him in the unfavorable intermediate group. The PSMA PET/CT shows no nodal or distant disease, so staging is complete. He is fit, and his life expectancy is estimated at about ten years, so curative treatment is reasonable. Observation, with treatment only if symptoms develop, is also a reasonable choice at his age and was discussed. Active surveillance is not recommended for Grade Group 3 disease. Radical prostatectomy is not advised at his age and after his earlier prostate operation, which raises the risk of incontinence. Brachytherapy is not advised because of the resection defect. The recommended option is external beam radiotherapy to the prostate with four to six months of androgen deprivation. [S]
- Short-term androgen deprivation with radiotherapy (Z79.899). In unfavorable intermediate-risk disease, adding four to six months of androgen deprivation to radiotherapy improves cancer control. Starting it about three months before radiotherapy also shrinks the gland. A GnRH agonist with an anti-androgen for the first weeks blocks the testosterone flare. The main effects to monitor are hot flashes, fatigue, sexual effects, weight gain, bone loss, metabolic and cardiovascular risk, and changes in mood or memory. [S]
- Earlier prostate operation and urinary function. The resection defect does not prevent external beam radiotherapy, but it slightly raises the risk of urinary irritation and, rarely, of a urethral stricture. Mild baseline symptoms (IPSS 7) are favorable. Moderate hypofractionation (60 Gy in 20 fractions or 70 Gy in 28) and conventional fractionation (74 to 80 Gy in 2 Gy fractions) give similar cancer control; after discussion of the shorter course and the lower dose per fraction, conventional fractionation of 74 Gy in 37 fractions was chosen. [S]
- Bone health before androgen deprivation. Low bone mass at the femoral neck with mild vitamin D insufficiency. Ten-year hip fracture risk is below 3 percent, so no bone drug is needed for a six-month course. [S]
Data reviewed: MRI prostate report and images, biopsy pathology, the first-visit PSA, testosterone, blood count, chemistry, A1c, lipids, and 25-hydroxyvitamin D, the PSMA PET/CT from two weeks ago (uptake confined to the left peripheral zone; no nodal, bone, or visceral disease), and the DXA scan from this morning (femoral neck T-score -1.4, lumbar spine -0.6). [S]
Plan of Treatment
- External beam radiotherapy to the prostate and proximal seminal vesicles, 74 Gy in 37 daily fractions with intensity modulation and daily image guidance on fiducial markers; no pelvic nodal radiation. [S]
- Androgen deprivation for six months: bicalutamide 50 mg daily for four weeks starting today, leuprolide 22.5 mg intramuscularly in one week at this clinic and a second dose twelve weeks later, with radiotherapy starting about three months after the first injection. [S]
- Fiducial markers and planning CT and MRI about two weeks before radiotherapy. [S]
- During androgen deprivation: testosterone and PSA at three months, blood pressure and weight at every visit, hot flashes, fatigue, mood, and cognition reviewed at each visit, and glucose and lipids yearly. [S]
- Bone health: vitamin D 1000 units daily with a recheck in three months, calcium from food, resistance exercise, and DXA every one to two years. [S]
- During radiotherapy: weekly review for urinary and bowel effects; tamsulosin if urinary frequency or a weak stream develops; report blood in the urine or stool. [S]
- After radiotherapy: PSA six weeks after treatment, then every six months for five years and yearly after that; recurrence is a PSA rise of 2 ng/mL above the nadir (Phoenix); a temporary PSA bounce is not recurrence. [S]
- Discussed with Dr. Mokoena today. The patient chose radiotherapy with six months of androgen deprivation after hearing each option, including observation, and agrees with the plan. [S]
- Follow-up: Leuprolide injection here in one week. Fiducial markers and planning in about twelve weeks. Weekly review during radiotherapy, then radiation oncology three months after treatment and every six months. Primary care manages the androgen deprivation monitoring, bone health, blood pressure, distress screening, and PSA surveillance between reviews. [S]